Trends in survival and treatment of SEGA: National Cancer Database Analysis
| Autor: | Ankit I. Mehta, Anisse N. Chaker, James S Ryoo, Mandana Behbahani, Ravi S. Nunna, Syed I. Khalid |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty Everolimus business.industry Database analysis Confounding Medicine (miscellaneous) Cancer Original Articles medicine.disease Chemotherapy regimen Clinical trial 03 medical and health sciences 0302 clinical medicine Internal medicine Epidemiology medicine 030212 general & internal medicine business 030217 neurology & neurosurgery Chemoradiotherapy medicine.drug |
| Zdroj: | Neurooncol Pract |
| ISSN: | 2054-2585 2054-2577 |
| Popis: | Background SEGA is a rare, slow-growing CNS neoplasm that has historically been treated by surgical resection. However, the advent of a mammalian target of rapamycin complex-1 inhibitor, everolimus, has shown promising results in recent clinical trials. We sought to provide an analysis of epidemiological and survival risk factors in this rare tumor entity, while comparing trends in surgical management before and after introduction of everolimus in SEGAs. Methods Patients with SEGA were queried from the National Cancer Database between 2004 and 2015. Standard statistical analysis was conducted to assess variables associated with the odds of performing surgery and survival, while controlling for confounding variables. Results A total of 460 patients were diagnosed with SEGA. Multivariable analysis of survival demonstrated that increased age was associated with decreased survival (HR, 1.05; P Conclusion Our analysis of SEGAs demonstrated that age was the only variable affecting overall survival. Surgical resection was performed in older patients with larger tumors (> 20 mm) as a primary mode of treatment, without chemoradiotherapy. Expectedly, rates of surgical resection were found to have decreased since 2011, after FDA approval of everolimus for SEGA treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|